Dupilumab as a combination therapy to oral systemic immunomodulators for moderate-to-severe atopic dermatitis for skin of color children in resource-limited setting: A case series

Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poo...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Indian Journal of Paediatric Dermatology
المؤلفون الرئيسيون:	Siti Nuraihan, M N Azmi, Sabeera Begum, Kin Fon Leong
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wolters Kluwer Medknow Publications 2023-01-01
الموضوعات:	atopic eczema children combination dupilumab oral immunomodulators resources limited setting skin of color
الوصول للمادة أونلاين:	http://www.ijpd.in/article.asp?issn=2319-7250;year=2023;volume=24;issue=3;spage=232;epage=235;aulast=Nuraihan